WO2024141791 - COMBINED DELIVERY OF ANTIGENS AND TOLEROGENIC SIGNALS VIA DUAL-SIZED HYDROGEL SPHERES AND MOF COMPOSITES FOR TYPE-1 DIABETES VACCINE DEVELOPMENT
National phase entry is expected:
Publication Number
WO/2024/141791
Publication Date
04.07.2024
International Application No.
PCT/IB2023/000798
International Filing Date
28.12.2023
Title **
[English]
COMBINED DELIVERY OF ANTIGENS AND TOLEROGENIC SIGNALS VIA DUAL-SIZED HYDROGEL SPHERES AND MOF COMPOSITES FOR TYPE-1 DIABETES VACCINE DEVELOPMENT
[French]
ADMINISTRATION COMBINÉE D'ANTIGÈNES ET DE SIGNAUX TOLÉROGÈNES PAR L'INTERMÉDIAIRE DE SPHÈRES D'HYDROGEL À DOUBLE TAILLE ET DE COMPOSITES MOF POUR LE DÉVELOPPEMENT D'UN VACCIN CONTRE LE DIABÈTE DE TYPE 1
Applicants **
THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY
Clear Water Bay, Kowloon
Hong Kong, CN
Inventors
CHUNG, Jin Teng
c/o The Hong Kong University of Science and Technology
Clear Water Bay, Kowloon
Hong Kong, CN
LAU, Chi Ming Laurence
c/o The Hong Kong University of Science and Technology
Clear Water Bay, Kowloon
Hong Kong, CN
CHAU, Ying
c/o The Hong Kong University of Science and Technology
Clear Water Bay, Kowloon
Hong Kong, CN
Priority Data
63/477,559
28.12.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CNIPA
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1369 | |
| EPO | Filing, Examination | 7847 | |
| Japan | Filing | 588 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 2710 |
Total: 13088 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
It pertains to a novel platform for the sustained release of Type-1 diabetes antigens. More specifically, it provides a combination of dual sized hydrogel particles for the delivery of Type-1 diabetes antigens and multi-component adjuvants to confer immune tolerance.[French]
La présente invention concerne une nouvelle plate-forme pour la libération prolongée d'antigènes du diabète de type 1. Plus spécifiquement, la présente invention concerne une combinaison de particules d'hydrogel de taille double pour l'administration d'antigènes du diabète de type 1 et d'adjuvants à composants multiples pour conférer une tolérance immunitaire.